Complete Filing Data
LakeShore Biopharma Co., Ltd. reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $107.48 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean LakeShore Biopharma Co., Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$100.0M | -$433.5M | -$145.5M | -$106.0M | -$191.8M |
| General And Administrative Expense | $129.0M | $140.1M | $72.9M | $98.1M | $155.3M |
| Research And Development Expense | $20.4M | $302.8M | $318.7M | $211.2M | $94.4M |
| Other Nonoperating Income Expense | -$657.3K | $10.6M | $551.8K | -$328.0K | $4.1M |
| Operating Income Loss | -$12.0M | -$445.8M | -$139.4M | -$119.0M | -$125.8M |
| Operating Expenses | $82.7M | $901.6M | $673.2M | $504.8M | $323.2M |
| Nonoperating Income Expense | -$2.0M | -$9.4M | -$5.0M | $17.9M | -$48.5M |
| Net Income Loss Available To Common Stockholders Basic | -$13.9M | -$433.5M | -$283.5M | -$236.7M | -$208.4M |
| Income Tax Expense Benefit | -$946.9K | -$21.7M | $1.1M | $4.9M | $17.5M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$14.1M | -$455.2M | -$144.3M | -$101.1M | -$174.4M |
| Gross Profit | $70.7M | $455.7M | $533.8M | $385.9M | $197.4M |
| Deferred Income Tax Expense Benefit | -$4.3M | -$21.7M | $1.1M | $4.9M | $17.5M |
| Amortization Of Intangible Assets | $963.8K | $6.8M | $7.0M | $6.7M | $5.7M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $126.5K | -$3.8M | -$137.5M | $38.9M | $22.5M |
| Interest Income Expense Net | -$2.2M | -$44.3M | -$30.9M | -$2.7M | -$29.7M |
| Revenues | $85.7M | $573.4M | $687.2M | $502.9M | $257.0M |
| Cost Of Revenue | $15.0M | $117.7M | $153.4M | $117.1M | $59.7M |
| Comprehensive Income Net Of Tax | -$99.1M | -$437.2M | -$283.0M | -$67.1M | -$169.4M |
| Deferred Income Tax Assets Net | $3.9M | $23.6M | $1.9M | $3.0M | |
| Late Fees Related To Taxes Other Than Income Tax | $3.6K | $231.2K | $7.3M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $107.5M | $246.6M | $370.4M | $271.1M | $390.5M | $2.1M |
| Stockholders Equity | $69.6M | $585.2M | $728.5M | -$699.0M | -$508.9M | -$847.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$139.1M | -$123.8M | $99.3M | -$119.4M | $388.4M | |
| Inventory Write Down | $68.2M | -$723.6K | $4.4M | $1.1M | ||
| Temporary Equity Accretion To Redemption Value Adjustment | $138.0M | $130.7M | $16.6M | |||
| Retained Earnings Accumulated Deficit | -$2.41B | -$2.31B | -$1.87B | -$1.59B | ||
| Property Plant And Equipment Net | $57.6M | $473.3M | $571.8M | $550.2M | ||
| Prepaid Expense And Other Assets Current | $632.0K | $7.4M | $10.4M | $8.0M | ||
| Other Assets Noncurrent | $10.3M | $34.4M | $20.9M | $28.2M | ||
| Operating Lease Right Of Use Asset | $118.0K | $7.3M | $11.1M | $14.9M | ||
| Operating Lease Liability Current | $63.7K | $5.2M | $4.8M | $4.3M | ||
| Long Term Debt Noncurrent | $23.5M | $99.0M | $293.8M | $253.9M | ||
| Liabilities Current | $824.8M | $802.2M | $658.8M | $475.9M | ||
| Liabilities And Stockholders Equity | $190.5M | $1.51B | $1.72B | $1.44B | ||
| Liabilities | $120.9M | $927.8M | $991.3M | $770.5M | ||
| Inventory Net | $31.7M | $203.4M | $185.4M | $166.5M | ||
| Intangible Assets Net Excluding Goodwill | $10.1M | $71.2M | $78.1M | $80.7M | ||
| Common Stock Value | $28.6K | $26.1K | $12.3K | $8.0K | ||
| Assets Noncurrent | $525.4M | $609.9M | $683.8M | $677.0M | ||
| Assets Current | $842.2M | $903.2M | $1.04B | $764.8M | ||
| Assets | $190.5M | $1.51B | $1.72B | $1.44B | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$8.0M | -$58.2M | -$54.4M | $83.1M | ||
| Accounts Receivable Net Current | $69.8M | $444.2M | $463.1M | $308.6M | ||
| Accounts Payable Current | $49.6M | $67.8M | $80.4M | $30.8M | ||
| Non Cash Lease Expense | $4.4M | $3.8M | $2.2M | |||
| Operating Lease Liability Noncurrent | $1.8M | $6.3M | $10.6M | |||
| Liabilities Noncurrent | $43.2M | $125.6M | $48.4M | $294.6M | ||
| Gain Loss On Sale Of Property Plant Equipment | -$9.8M | -$13.1K | -$274.0K | -$24.9K | ||
| Repayments Of Debt | $2.9M | $23.6M | $160.4M | |||
| Operating Right Of Use Assets Recognized For Related Operating Lease Liabilities | $48.2K | $1.5M | $15.0M | |||
| Deferred Government Grants Non Current | $3.4M | $30.1M | ||||
| Deferred Government Grants Current | $334.1K | $2.3M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Payments To Acquire Property Plant And Equipment | $1.8M | $44.3M | $52.8M | $295.3M | $104.9M |
| Net Cash Provided By Used In Investing Activities | -$17.0M | -$44.3M | -$57.0M | -$298.9M | -$104.2M |
| Net Cash Provided By Used In Financing Activities | -$3.6M | $205.3M | $317.4M | $364.6M | $739.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$7.5M | $5.3M | -$9.0M | -$59.2M | -$146.8M |
| Increase Decrease In Operating Lease Liability | -$5.3M | -$5.1M | -$4.6M | -$3.8M | -$2.2M |
| Increase Decrease In Inventories | $24.2M | $86.3M | $18.2M | $89.5M | $68.7M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$1.5M | $53.2M | $43.0M | -$35.6M | $140.2K |
| Increase Decrease In Accounts Receivable | $59.6M | -$13.9M | $165.2M | $99.1M | $220.7M |
| Net Cash Provided By Used In Operating Activities | -$121.0M | -$295.2M | -$182.5M | -$173.5M | -$246.6M |
| Share Based Compensation | $13.6M | $9.8M | $3.5M | $7.8M | $76.8M |
| Proceeds From Sale Of Property Plant And Equipment | $852.1K | $68.0K | $8.0K | $644.8K | |
| Proceeds From Issuance Of Debt | $334.8M | $337.9M | $247.4M | $414.1M | $32.3M |
| Increase Decrease In Deferred Government Grants | -$938.2K | -$656.7K | -$44.3K | ||
| Payments To Acquire Intangible Assets | $717.5K | $4.3M | $3.6M | ||
| Increase Decrease In Accounts Payable | -$18.2M | -$12.7M | $49.6M | $14.4M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $1.5M | $21.3M | -$11.5M | -$2.7K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-5.22 | $-40.54 | $-23.55 | $-1.71 | $-3.10 |
| Earnings Per Share Basic | $-5.22 | $-40.54 | $-23.55 | $-1.71 | $-3.10 |
| Weighted Average Number Of Shares Outstanding Basic | 19.2M | 10.7M | 6.2M | 61.8M | 61.8M |
| Weighted Average Number Of Diluted Shares Outstanding | 19.2M | 10.7M | 6.2M | 61.8M | 61.8M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Late Fees Related To Social Security Insurance | $454.9K | $756.2K | $747.6K | $1.9M | $7.7M |
| Interest Paid Net | $3.2M | $30.1M | $27.3M | $2.4M | $8.1M |
| Depreciation | $29.7M | $35.4M | $29.7M | $24.5M | $22.2M |
| Government Grants Income | $26.1M | $23.0M | $3.5M | ||
| Accretion To Redemption Value Of Convertible Redeemable Preferred Shares | 20.1M | 130.7M | 16.6M | ||
| Advance To Suppliers Current | $6.8M | $10.6M |
Most recent annual filing with the SEC: July 31, 2025
Data sourced from SEC EDGAR public filings as of August 9, 2026.